<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620904</url>
  </required_header>
  <id_info>
    <org_study_id>2015-5689</org_study_id>
    <nct_id>NCT02620904</nct_id>
  </id_info>
  <brief_title>Mifepristone Induction for Fetal Demise</brief_title>
  <acronym>MIFD</acronym>
  <official_title>Mifepristone Induction for Fetal Demise, a Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methods: Double blinded, randomized controlled trial with 1:1 allocation of mifepristone or&#xD;
      placebo at initiation of induction of labor for fetal demise 20 weeks estimated gestational&#xD;
      age or greater.&#xD;
&#xD;
      Hypothesis: Mifepristone will expedite time to delivery of fetus among demise patients, when&#xD;
      compared to placebo, and in conjunction with other pharmacologic methods for induction of&#xD;
      labor.&#xD;
&#xD;
      Expected outcomes: The addition of a progesterone receptor modulator will expedite time to&#xD;
      delivery of the fetus and ultimately improve the experience associated with induction of&#xD;
      labor for fetal demise.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a double blinded, randomized, placebo-controlled clinical trial at&#xD;
      the time of initiation of induction of labor for fetal demise at 20 weeks gestational age or&#xD;
      greater.&#xD;
&#xD;
        1. Diagnose fetal demise: confirm absence of fetal heart motion by attending physician as&#xD;
           per the institutional standards and protocols.&#xD;
&#xD;
        2. Confirm gestational age at presentation to labor and delivery based on available medical&#xD;
           records and/or ultrasonography as per standard practice and institutional protocols.&#xD;
&#xD;
        3. Based on inclusion and exclusion criteria potential participants will be informed about&#xD;
           the research, offered the opportunity to contribute, and trained research staff will&#xD;
           complete the informed consent process. After documentation of consent and discussion of&#xD;
           the research as indicated the participants will be randomized to the intervention or&#xD;
           control arm. Both groups will receive emotional and physical support with induction of&#xD;
           labor as per practice guidelines and standard of care by Montefiore physicians, faculty&#xD;
           and staff irrespective of participation or assignment.&#xD;
&#xD;
        4. Interventional Arm: Ingest 200mg tab of mifepristone orally. This will coincide with or&#xD;
           be implemented prior to the initiation of the induction of labor plan as delineated by&#xD;
           the attending physician. The timing will be sensitive to the needs of the participant&#xD;
           and the labor and delivery room staff.&#xD;
&#xD;
        5. Control Arm: Ingest a placebo tab orally with similar physical properties. This will&#xD;
           coincide with or be implemented prior to the initiation of the induction of labor plan&#xD;
           as delineated by the attending physician. The timing will be sensitive to the needs of&#xD;
           the participant and the labor and delivery room staff.&#xD;
&#xD;
        6. Montefiore protocol for induction of labor: will follow institutional standards.&#xD;
&#xD;
        7. Data: Patient data will be collected by the Labor and Delivery staff via electronic&#xD;
           medical record or paper record that will be scanned into the electronic medical record.&#xD;
           The investigators will use data abstraction tools to collect information such as time of&#xD;
           medication administration, medications administered, time of delivery of fetus, duration&#xD;
           of admittance to labor and delivery, and postpartum course, or complications from the&#xD;
           electronic medical record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to recruit. Projected completion was 2018 however, enrollment and recruitment were&#xD;
    difficult. The study was terminated due to inability to enroll.&#xD;
  </why_stopped>
  <start_date type="Actual">July 14, 2016</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Delivery of Fetus</measure>
    <time_frame>From the initiation of medical therapy for induction to delivery of fetus, assessed up to 36 hours</time_frame>
    <description>From the initiation of medical therapy for induction to delivery of fetus, assessed up to 36 hours</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Intrauterine Fetal Demise</condition>
  <condition>Fetal Death</condition>
  <arm_group>
    <arm_group_label>mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <arm_group_label>mifepristone</arm_group_label>
    <other_name>RU486, RU46, mifeprex, mifegen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Intrauterine fetal death as confirmed by absence of cardiac motion on ultrasound by&#xD;
             Attending physician at the time of admission to the hospital.&#xD;
&#xD;
          2. Estimated gestational age greater than 20 weeks&#xD;
&#xD;
          3. Hemodynamically stable and appropriate for induction of labor as per primary clinical&#xD;
             health team in house&#xD;
&#xD;
          4. Women with one prior low transverse cesarean delivery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of 2 or more low transverse cesarean deliveries&#xD;
&#xD;
          2. Prior classical cesarean delivery&#xD;
&#xD;
          3. History of abdominal myomectomy&#xD;
&#xD;
          4. Known or suspected allergic reaction to mifepristone&#xD;
&#xD;
          5. Known or suspected adrenal gland disease&#xD;
&#xD;
          6. Known or suspected bleeding diatheses or coagulopathies&#xD;
&#xD;
          7. Known or suspected use of QTc-prolonging medication&#xD;
&#xD;
          8. Known maternal medical or physical conditions that prohibits vaginal delivery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Atrio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 1, 2015</study_first_submitted>
  <study_first_submitted_qc>December 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>January 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2021</results_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Jessica Atrio</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>mifepristone</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>vaginal delivery</keyword>
  <keyword>progesterone receptor modulator</keyword>
  <keyword>induction of labor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fetal Death</mesh_term>
    <mesh_term>Stillbirth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02620904/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT02620904/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone</title>
          <description>following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
Mifepristone</description>
        </group>
        <group group_id="P2">
          <title>Placebo Pill</title>
          <description>following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone</title>
          <description>following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
Mifepristone</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill</title>
          <description>following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Delivery of Fetus</title>
        <description>From the initiation of medical therapy for induction to delivery of fetus, assessed up to 36 hours</description>
        <time_frame>From the initiation of medical therapy for induction to delivery of fetus, assessed up to 36 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
Mifepristone</description>
          </group>
          <group group_id="O2">
            <title>Placebo Pill</title>
            <description>following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Delivery of Fetus</title>
          <description>From the initiation of medical therapy for induction to delivery of fetus, assessed up to 36 hours</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="3" upper_limit="27"/>
                    <measurement group_id="O2" value="20" lower_limit="2" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed during hospitalization, an average of 3 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone</title>
          <description>following informed consent women will be randomized and the mifepristone group will take 200 mg by mouth immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
Mifepristone</description>
        </group>
        <group group_id="E2">
          <title>Placebo Pill</title>
          <description>following informed consent women will be randomized and the placebo group will take a placebo pill by mouth (similar in properties to the mifepristone group, but it will lack any active drug) immediately prior to induction of labor for fetal demise on labor and delivery&#xD;
placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to difficulty with recruitment the study was unable to be completed in the projected time frame. Despite efforts to enhance recruitment and extending the study duration very few persons were enrolled. Due to the limited enrollment no conclusions can be ascertained about the impact of mifepristone on the induction of labor in this setting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jessica Maria Atrio</name_or_title>
      <organization>Montefiore Einstein</organization>
      <phone>7184058260</phone>
      <email>jatrio@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

